<DOC>
	<DOC>NCT01024062</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent non-small cell lung cancer</brief_summary>
	<brief_title>Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients with no prior chemotherapy who meet either of the listed below: Patient with stage IIIB or IV disease Patients with recurrent disease following potentially curative surgical resection Patients with previous chemotherapy up to one regimen Patients with serious, uncontrolled medical illness Patients with previous therapy with taxanes</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>